Premium
Symptomatic Epstein–Barr virus reactivation in a patient with acute myeloid leukaemia and treatment with the monoclonal anti‐CD20 antibody rituximab
Author(s) -
Tinchon Christoph,
Auner Holger W.,
BehamSchmid Christine,
Aberle Stephan W.,
Sill Heinz,
Linkesch Werner
Publication year - 2002
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1034/j.1600-0609.2002.02740.x
Subject(s) - rituximab , medicine , fludarabine , monoclonal antibody , virology , cd20 , immunology , virus , monoclonal , regimen , antibody , myeloid , chemotherapy , cyclophosphamide
In a patient with acute myeloid leukaemia, treated with several courses of chemotherapy including a fludarabine‐containing regimen, severe symptoms due to Epstein–Barr virus reactivation occurred but could be successfully treated with the monoclonal anti‐CD20 antibody rituximab. Depletion of viral host cells may be effective in treatment of symptoms due to Epstein–Barr virus reactivation.